Gleevec is a drug used to treat different types of leukemia and other cancers of the blood, gastrointestinal stromal tumors, skin tumors called dermatofibrosarcoma protuberans, and a rare condition called systemic mastocytosis. It is also being studied in the treatment of other types of cancer. Gleevec blocks the protein made by the bcr/abl oncogene. It is a type of tyrosine kinase inhibitor. Also called imatinib mesylate and STI571.
The Centers for Medicare & Medicaid Services has announced it is adding two more drugs to the list of drugs covered under a Medicare demonstration program providing substantial savings to beneficiaries with serious diseases, including cancer, multiple sclerosis, and rheumatoid arthritis.
A handful of leukemia cells constantly replenish the supply of cancerous cells, according to new work by Stanford University School of Medicine researchers.
Hotspots in two areas of a gene that encodes a specific signaling enzyme, or kinase, are vulnerable to a variety of mutations found in five types of brain cancers, according to a report published in the August 1 issue of the journal Cancer Research.
One of the truly spectacular success stories in modern oncology is the development and implementation of Gleevec, a drug that virtually halts the progress of chronic myeloid leukemia. Yet for some patients who harbor particularly stubborn genetic mutations, Gleevec fails miserably.
Cancer treatments, including the most commonly used chemotherapy agents as well as the newest biologic and targeted therapy drugs, can harm a patient’s heart, sometimes fatally
50,000 people or 10% of the 500,000 people in the U.S with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery for coverage of life saving drugs.
HHS Secretary Tommy G. Thompson today announced a new Medicare demonstration program that will save seniors and persons with disabilities substantial money
A drug originally developed to block the formation of blood vessels in tumors has been shown to overcome resistance to treatment with Gleevec in patients with gastrointestinal stromal tumors (GIST).
In the hunt for new cancer drug targets, scientists from the Johns Hopkins Kimmel Cancer Center and the Howard Hughes Medical Institute have discovered mutations in a family of genes linked to more than a quarter of colon cancers, as well as several other common cancers including breast and lung.
A pair of studies at UCLA's Jonsson Cancer Center that takes laboratory science to the patients' bedside found that combining the molecularly targeted therapy Herceptin with a specific chemotherapy combination resulted in significant tumor response rates and longer relapse-free periods in women with an aggressive form of advanced breast cancer.
Dana-Farber Cancer Institute Researchers, sensing an opening in the cancer battle, are mounting a quick thrust to flush out suspected molecular cancer triggers in tumor cells.
Mutation of a gene involved in non-small cell lung cancer (NSCLC) increases the likelihood that the drug gefitinib (Iressa™) will show a beneficial response, researchers at the Dana-Farber Cancer Institute, the National Cancer Institute (NCI) - part of the National Institutes of Health - and two other institutions announced today in the online version of Science.
A gene known to promote longevity in animals has now been discovered to encode a tumor suppressor – a protein that helps prevent cancer, according to a study by a team of scientists from The University of Texas M. D. Anderson Cancer Center. The new gene, which was inactivated in two-thirds of patients studied, presents a potent new target for breast cancer therapy, the researchers say.
St. John’s wort, an herb thought to be a safe, natural remedy for mild depression, may interfere with a powerful cancer-fighting drug’s ability to prevent relapse in leukemia patients, a University of Florida pharmacy researcher will report March 27 at the annual meeting of the American Society for Clinical Pharmacology and Therapeutics.
Scientists at the Johns Hopkins Kimmel Cancer Center and Howard Hughes Medical Institute have found mutations in a gene linked to the progression of colon and other cancers. The research findings, may lead to new therapies and diagnostic tests that target this gene.